Qualigen Therapeutics Strengthens Leadership with Key Appointments
Key Leadership and Governance Changes at Qualigen Therapeutics
Qualigen Therapeutics, Inc. (NASDAQ: QLGN) has announced pivotal changes aimed at bolstering its executive team and enhancing operational transparency. These measures reflect the company's dedication to driving forward its strategic growth agenda.
Exciting Executive Appointments
As of October 2, 2025, Qualigen Therapeutics has appointed Jerry (Jiawei) Wang as Co-Chief Executive Officer alongside Koti Meka, who steps into the role of Chief Financial Officer. This duo brings a wealth of experience and a strong background in operational and financial management.
Mr. Wang, formerly the Global President of Faraday Future, has played a crucial role in the company's development since its inception in 2014. He has successfully raised over $3 billion in funding and facilitated the company's IPO in 2021, positioning him as a key player in the industry.
Prior to joining Qualigen, Mr. Meka was the CFO of Faraday Future as well, where he amassed valuable experience from his tenure at Ford Motor Company. His expertise spans cost optimization and corporate finance, making him an asset to the new leadership team.
Expanding Board of Directors
In conjunction with a successful private placement executed recently, Qualigen's Board of Directors has welcomed three new members who bring diverse expertise:
- Kevin Chen, Independent Director
- Chad Chen, Director
- Jay Sheng, Director
These additions aim to bolster the governance framework of the company further. Notably, Mr. Sheng, who is also connected with Faraday Future, is now the Chairman of the Audit Committee, while both Graydon Bensler and Chad Chen join as members.
Mr. Kevin Chen currently holds the position of Chief Economist and Chief Investment Officer at Horizon Financial. He has an extensive portfolio of board roles across various public companies, Reflecting his well-rounded expertise. His academic contributions as an adjunct professor at New York University and guest speaker at elite institutions underscore his deep knowledge in the industry.
Meanwhile, Mr. Chad Chen contributes his legal acumen as a partner at Yoka | Smith, LLP, where he specializes in representing clients in several industries. His background in both litigation and non-litigation matters positions him well to navigate the complexities of corporate governance.
Auditor Transition for Enhanced Oversight
On October 3, 2025, Qualigen transitioned to a new auditing firm, Macias Gini & O’Connell LLP (“MGO”), to provide oversight for the fiscal year concluding December 31, 2025. This firm also provides audit services for Faraday Future, further strengthening ties between the two companies.
Previously, on October 1, 2025, WhitumSmith+Brown, PC notified the Company of its resignation as the independent registered public accounting firm for Qualigen. Importantly, this change was amicable and arose without any disagreements regarding operations or policies, ensuring a smooth transition.
“These appointments signify a vital step forward for Qualigen Therapeutics,” stated Kevin Richardson, Co-CEO. “With strengthened leadership and new board expertise, we are well-positioned to advance our long-term growth strategy while building shareholder trust and value.”
About Qualigen Therapeutics, Inc.
Qualigen Therapeutics, Inc. (NASDAQ: QLGN), based in California, is a biotechnology company dedicated to developing innovative treatments in oncology and immunology. The company is passionately pursuing strategic initiatives that leverage advanced technologies and innovations, aiming to accelerate its global growth trajectory.
Investor and Media Contact
Investor Relations Department
Qualigen Therapeutics, Inc.
5857 Owens Avenue, Suite 300, Carlsbad, CA 92008
Tel: +1 (760) 452-8111
Email: info@qualigeninc.com
Frequently Asked Questions
What leadership changes have been made at Qualigen Therapeutics?
Qualigen has appointed Jerry Wang as Co-CEO and Koti Meka as CFO to strengthen its executive team.
Who are the new members of the Board of Directors?
The Board has appointed Kevin Chen, Chad Chen, and Jay Sheng as new members to enhance governance and oversight.
What is the reason for the auditor transition?
The transition to Macias Gini & O’Connell LLP aims to enhance the quality and oversight of financial audits for the upcoming fiscal year.
How does this change impact shareholders?
These appointments and structural changes are intended to build shareholder trust, improve transparency, and facilitate long-term growth.
What is Qualigen's focus area as a biotechnology company?
Qualigen Therapeutics focuses on developing advanced therapeutics in oncology and immunology, along with integrating innovative technologies.
About The Author
Contact Ryan Hughes privately here. Or send an email with ATTN: Ryan Hughes as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
